Cibus Inc.
11/18/2024 | Press release | Distributed by Public on 11/18/2024 16:03
Management Change/Compensation Form 8 K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On November 18, 2024, the Board of Directors (the "Board") of Cibus, Inc. (the "Company") appointed August Moretti to serve as a member of the Board, effective as of such date. Mr. Moretti will also serve as a member of the Board's Audit Committee, effective as of such date.
Mr. Moretti, 74, has extensive operating and financial executive experience in all phases of company growth and funding, from early-stage development to product approval and commercialization. Mr. Moretti is currently self-employed as a consultant. From 2019 until his retirement in September 2023, Mr. Moretti served as the Chief Financial Officer of 4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company. Mr. Moretti previously served as Chief Financial Officer at Assertio Therapeutics (formerly Depomed, Inc.), a specialty pharmaceuticals company focused in pain and neurology, from January 2012 until August 2018. Prior to this, Mr. Moretti served as Chief Financial Officer and Senior Vice President of Alexza Pharmaceuticals, Inc., a pharmaceutical company, and as Chief Financial Officer and General Counsel of Alavita, Inc., a personalized medicine company. Earlier in his career, Mr. Moretti was a partner in an international law firm, where his practice included representation of life science companies on issues relating to public and private financings, mergers and acquisitions, corporate governance, disclosure and public reporting. Mr. Moretti received his B.A. in Economics from Princeton University in 1972. He received his J.D. from Harvard Law School in 1975.
There are no arrangements or understandings between Mr. Moretti and any other persons pursuant to which Mr. Moretti was named as a director of the Board. Mr. Moretti has no direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K.
In accordance with the Company's customary practice, the Company entered into its standard form of indemnification agreement for directors and executive officers with Mr. Moretti in connection with his appointment to the Board. Mr. Moretti will receive annual compensation pursuant to the terms of the Cibus, Inc. Non-Employee Director Compensation Policy, as described in the Company's Definitive Proxy Statement for the 2024 Annual Meeting of Stockholders.
Officers; Compensatory Arrangements of Certain Officers.
On November 18, 2024, the Board of Directors (the "Board") of Cibus, Inc. (the "Company") appointed August Moretti to serve as a member of the Board, effective as of such date. Mr. Moretti will also serve as a member of the Board's Audit Committee, effective as of such date.
Mr. Moretti, 74, has extensive operating and financial executive experience in all phases of company growth and funding, from early-stage development to product approval and commercialization. Mr. Moretti is currently self-employed as a consultant. From 2019 until his retirement in September 2023, Mr. Moretti served as the Chief Financial Officer of 4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company. Mr. Moretti previously served as Chief Financial Officer at Assertio Therapeutics (formerly Depomed, Inc.), a specialty pharmaceuticals company focused in pain and neurology, from January 2012 until August 2018. Prior to this, Mr. Moretti served as Chief Financial Officer and Senior Vice President of Alexza Pharmaceuticals, Inc., a pharmaceutical company, and as Chief Financial Officer and General Counsel of Alavita, Inc., a personalized medicine company. Earlier in his career, Mr. Moretti was a partner in an international law firm, where his practice included representation of life science companies on issues relating to public and private financings, mergers and acquisitions, corporate governance, disclosure and public reporting. Mr. Moretti received his B.A. in Economics from Princeton University in 1972. He received his J.D. from Harvard Law School in 1975.
There are no arrangements or understandings between Mr. Moretti and any other persons pursuant to which Mr. Moretti was named as a director of the Board. Mr. Moretti has no direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K.
In accordance with the Company's customary practice, the Company entered into its standard form of indemnification agreement for directors and executive officers with Mr. Moretti in connection with his appointment to the Board. Mr. Moretti will receive annual compensation pursuant to the terms of the Cibus, Inc. Non-Employee Director Compensation Policy, as described in the Company's Definitive Proxy Statement for the 2024 Annual Meeting of Stockholders.